Results from Rybrevant trial solidify Janssen’s foothold in EGFR-mutated NSCLC
Currently, NSCLC patients with EGFR exon 19 deletions or L858R substitution face limited therapeutic options after seeing disease progression post-front-line treatment.
Currently, NSCLC patients with EGFR exon 19 deletions or L858R substitution face limited therapeutic options after seeing disease progression post-front-line treatment.
What's Your Reaction?
